Back to Atlas
CTransientStandard research/education caution
CMP-0423
Research
Polymyxin B nonapeptide (PMBN)
Antimicrobial / Barrier
Primarily research use as Gram-negative membrane sensitizer; not an enhancement compound
Reading this compound Reference only
Information below is educational. Dosing, mechanisms and status fields are compiled from the source list at the bottom of this page — always verify against a licensed clinician before use.
Reference-only summary of publicly discussed or source-listed patterns. Not medical advice and not a personal recommendation.
Mechanism & Use
- Compound type
- Peptide antibiotic fragment
- Primary mechanism
- LPS outer-membrane permeabilization without full polymyxin nephrotoxicity profile
- Primary market use
- Antimicrobial research
Pharmacology
- Molecular weight (Da)
- ~963.1
- Oral bioavailability
- N/A (peptide; not oral)
- Half-life
- ~5–60 min parent peptide; analogs may be longer
- Route tags
- SubQ; Injectable; route-dependent
- Evidence level
- Preclinical
- Clinical status
- Research
- Value-for-money score
- 1 / 10
Reported protocol signal
No clean popular protocol found in uploaded sources; create as research/reference entry and verify before public protocol display.
For orientation only. See disclaimer — always consult a licensed clinician before use.
Notes
Included for completeness; low relevance to cosmetic/metabolic/cognitive enhancement